sj-docx-1-tam-10.1177_17588359231181500 – Supplemental material for A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium

Supplemental material, sj-docx-1-tam-10.1177_17588359231181500 for A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium by Lise Verbruggen, Lisa Verheggen, Greetje Vanhoutte, Catherine Loly, Willem Lybaert, Ivan Borbath, Philippe Vergauwe, Koen Hendrickx, Celine Debeuckelaere, Amy de Haar-Holleman, Jean-Luc Van Laethem and Marc Peeters in Therapeutic Advances in Medical Oncology</p

Consort Diagram.

<p>Consort Diagram.</p

Classes of metabolic responses.

<p>Class 1: no metabolic unresponsive lesion; Class 2: minority of unresponsive lesion among whole body target tumour load; Class 3: majority of whole body target tumour load does not respond; Class 4: all target lesions are non-responding, or, presence of progressive lesions [progression defined as >25% increase of FDG uptake on second PET, or appearance of a new lesion].</p

PFS* (A) and OS* (B) distribution according to the 4 classes of metabolic response.

<p>Class 1: no metabolic unresponsive lesion; Class 2: minority of unresponsive lesion among whole body target tumour load; Class 3: majority of whole body target tumour load does not respond; Class 4: all target lesions are non-responding, or, presence of progressive lesions [progression defined as >25% increase of FDG uptake on second PET, or appearance of a new lesion]. *from date of the second FDG PET-CT.</p

PFS and OS distribution according to the dichotomized mR classifications.

<p>PFS and OS distribution according to the dichotomized mR classifications.</p

Most important (>10%) side effects in the 88 patients who received treatment according to Common Toxicity Criteria CTC3.0.

<p><b>Uncommon side effects</b>: gastrointestinal perforations (<i>N</i> = 2), acute pancreatitis (N = 1), digestive haemorrhages (<i>N</i> = 2), septic shock (<i>N</i> = 1), thromboembolic events (<i>N</i> = 2), and hiccups (<i>N</i> = 2)</p><p>Most important (>10%) side effects in the 88 patients who received treatment according to Common Toxicity Criteria CTC3.0.</p